Brainstorm cell therapeutics announces peer-reviewed publication of biomarker data from nurown's® phase 3 clinical trial in als

Nurown treatment resulted in a positive impact on important csf biomarkers relevant to als compared to placebo.significant changes in multiple als disease pathways support nurown's mechanism of action and complement clinical effects observed in als. new york , april 10, 2024 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of phase 3 biomarker data in muscle and nerve.
BCLI Ratings Summary
BCLI Quant Ranking